ProCyte Corp. announced Tuesday that it is expanding PhaseI/II clinical trials on its peptide-copper drug to treatinflammatory bowel disease (IBD).

The drug, Iamin-IB, apparently promotes an anti-inflammatoryresponse and induces growth of epithelial tissue, both of whichare important to healing.

In preliminary trials, Iamin-IB was administered in a retentionenema to patients whose disease did not respond toconventional IBD treatments. The clinical investigatorrecommended expanding the four-week treatment period tofurther evaluate the drug's safety and potential therapeuticeffects, the Kirkland, Wash., company (NASDAQ:PRCY) said.

ProCyte estimated that ulcerative colitis and Crohn's disease,the most common forms of inflammatory bowel disease, affect2 million people in the U.S.

(c) 1997 American Health Consultants. All rights reserved.

No Comments